176 related articles for article (PubMed ID: 28166654)
1. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.
Sufit RL; Ajroud-Driss S; Casey P; Kessler JA
Amyotroph Lateral Scler Frontotemporal Degener; 2017 May; 18(3-4):269-278. PubMed ID: 28166654
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor.
Kessler JA; Shaibani A; Sang CN; Christiansen M; Kudrow D; Vinik A; Shin N;
Clin Transl Sci; 2021 May; 14(3):1176-1184. PubMed ID: 33465273
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo-controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor.
Perin E; Loveland L; Caporusso J; Dove C; Motley T; Sigal F; Vartivarian M; Oliva F; Armstrong DG;
Int Wound J; 2023 Nov; 20(9):3531-3539. PubMed ID: 37230802
[TBL] [Abstract][Full Text] [Related]
4. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP-100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial.
Warita H; Kato M; Asada R; Yamashita A; Hayata D; Adachi K; Aoki M
J Clin Pharmacol; 2019 May; 59(5):677-687. PubMed ID: 30536581
[TBL] [Abstract][Full Text] [Related]
6. Six-Minute Walk Test as a Measure of Walking Capacity in Ambulatory Individuals With Amyotrophic Lateral Sclerosis.
Sanjak M; Langford V; Holsten S; Rozario N; Patterson CGM; Bravver E; Bockenek WL; Brooks BR
Arch Phys Med Rehabil; 2017 Nov; 98(11):2301-2307. PubMed ID: 28465220
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis.
Pascuzzi RM; Shefner J; Chappell AS; Bjerke JS; Tamura R; Chaudhry V; Clawson L; Haas L; Rothstein JD
Amyotroph Lateral Scler; 2010 May; 11(3):266-71. PubMed ID: 19961264
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
10. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
[No Abstract] [Full Text] [Related]
11. Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.
Ajroud-Driss S; Christiansen M; Allen JA; Kessler JA
Mol Ther; 2013 Jun; 21(6):1279-86. PubMed ID: 23609019
[TBL] [Abstract][Full Text] [Related]
12. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study.
Henry TD; Hirsch AT; Goldman J; Wang YL; Lips DL; McMillan WD; Duval S; Biggs TA; Keo HH
Gene Ther; 2011 Aug; 18(8):788-94. PubMed ID: 21430785
[TBL] [Abstract][Full Text] [Related]
13. Human hepatocyte growth factor (VM202) gene therapy via transendocardial injection in a pig model of chronic myocardial ischemia.
Perin EC; Silva GV; Vela DC; Zheng Y; Baimbridge F; Gahremanpour A; Quan X; Hahn W; Kim J; Wood K; Kitamura M
J Card Fail; 2011 Jul; 17(7):601-11. PubMed ID: 21703533
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial.
Syková E; Rychmach P; Drahorádová I; Konrádová Š; Růžičková K; Voříšek I; Forostyak S; Homola A; Bojar M
Cell Transplant; 2017 Apr; 26(4):647-658. PubMed ID: 27938483
[TBL] [Abstract][Full Text] [Related]
15. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
16. Muscle changes in amyotrophic lateral sclerosis: a longitudinal ultrasonography study.
Arts IMP; Overeem S; Pillen S; Jurgen Schelhaas H; Zwarts MJ
Clin Neurophysiol; 2011 Mar; 122(3):623-628. PubMed ID: 20810308
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis.
Shefner JM; Wolff AA; Meng L; Bian A; Lee J; Barragan D; Andrews JA;
Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(5-6):426-435. PubMed ID: 26982815
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study.
Nefussy B; Artamonov I; Deutsch V; Naparstek E; Nagler A; Drory VE
Amyotroph Lateral Scler; 2010; 11(1-2):187-93. PubMed ID: 19449238
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study.
Vázquez-Costa JF; Máñez I; Alabajos A; Guevara Salazar M; Roda C; Sevilla T
J Neurol; 2016 Oct; 263(10):1954-60. PubMed ID: 27383643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
